Navigation Links
CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
Date:2/20/2009

- 64 percent year-over-year increase in Ranexa(R) net revenue -

- Company retires more than $100 million in convertible debt in 2008 -

- Ranexa prescriptions for first week in February hit record high according to IMS -

PALO ALTO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the fourth quarter and full year ended December 31, 2008.

For the year ended December 31, 2008, the company reported a net loss of $98.5 million, or $1.61 per share, compared to a net loss of $181.0 million, or $3.05 per share, for the year ended December 31, 2007. This $1.44 per share reduction represents a 47 percent improvement in net loss from 2007 to 2008. For the quarter ended December 31, 2008, the company reported a net loss of $37.0 million, or $0.60 per share. This compares to a net loss of $34.1 million, or $0.57 per share, for the same quarter in 2007.

"2008 was an exceptional year for CV Therapeutics and its shareholders, as we received three major regulatory approvals, retired more than $100 million in debt, completed two major strategic transactions bringing in more than $250 million in non-dilutive net cash, grew our Ranexa business by 64 percent year-over-year, and saw our share price outperform the NASDAQ by more than 40 percent," said Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics.

"With the company's solid cash position, the full promotional launch of the improved U.S. Ranexa labeling and the imminent introduction of Ranexa in Europe, we expect 2009 to be another outstanding year, highlighted by increasing revenues and pipeline advancement with CVT-3619 and other programs. We expect to be able to provide an update regarding profitability timing by the middle of the year," La
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... WASHINGTON, Nov. 30Ultra-tiny zinc oxide (ZnO) particles with ... the ingredients list of some commercially available sunscreen products, ... beneath the outer layer of skin. To help ... from Australia and Switzerland have developed a way to ...
... to improve the efficiency and effectiveness of experimental gene ... new research report published in the December 2011 issue ... The report describes how scientists from Germany combined two ... that facilitate the exchange of genetic material between DNA ...
... or broiled fish on a weekly basis may be ... developing mild cognitive impairment (MCI) and Alzheimer,s disease, according ... of the Radiological Society of North America (RSNA). ... relationship between fish consumption, brain structure and Alzheimer,s risk," ...
Cached Biology News:Scientists use laser imaging to assess safety of zinc oxide nanoparticles in sunscreen 2The newest of the new in gene therapy: 'Tag and target and exchange' 2Eating fish reduces risk of Alzheimer's disease 2
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Biology Products: